Nov 2 (Reuters) - AstraZeneca PLC AZN.L :
* FUSION PHARMACEUTICALS ANNOUNCES COLLABORATION WITH ASTRAZENECA TO DEVELOP AND COMMERCIALIZE NEXT-GENERATION RADIOPHARMACEUTICALS AND COMBINATION THERAPIES
* FUSION PHARMACEUTICALS INC - AGREEMENT INCLUDES AN UPFRONT PAYMENT FROM ASTRAZENECA, AS WELL AS FUTURE DEVELOPMENT MILESTONE AND OTHER PAYMENTS
* FUSION PHARMACEUTICALS INC - AGREEMENT INCLUDES AN UPFRONT PAYMENT FROM ASTRAZENECA, AS WELL AS FUTURE DEVELOPMENT MILESTONE AND OTHER PAYMENTS
* FUSION PHARMACEUTICALS INC - FUSION AND ASTRAZENECA WILL JOINTLY DISCOVER, DEVELOP AND HAVE OPTION TO CO-COMMERCIALIZE NOVEL TATS IN UNITED STATES
* FUSION PHARMACEUTICALS INC - BOTH COMPANIES WILL HAVE A 50/50 PROFIT AND LOSS SHARE ON A WORLDWIDE BASIS.
* FUSION PHARMACEUTICALS INC - COMPANIES WILL ALSO EVALUATE POTENTIAL COMBINATION STRATEGIES INVOLVING EXISTING ASSETS IN THEIR RESPECTIVE PORTFOLIOS
* FUSION PHARMACEUTICALS - FUSION WILL CONDUCT PRECLINICAL DEVELOPMENT. ASTRAZENECA WILL CONDUCT AND FUND CLINICAL DEVELOPMENT OF COMBINATION THERAPIES